Trial reportHeart (British Cardiac Society)2008
Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome.
Trial report in Heart (British Cardiac Society), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Prediction of key regulators and downstream targets of E. coli induced mastitis.Journal of applied genetics · 2019Pooled it
- Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency.Journal of clinical lipidologyTrial
- Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.Nature reviews. Cardiology · 2026Review
- Prognostic Utility of the Cytokine Profile for Predicting Major Adverse Cardiovascular Events in Acute Myocardial Infarction Following Percutaneous Coronary Intervention.International journal of general medicine · 2026Article
- Role of interleukins in the pathogenesis of coronary heart disease: A literature review.World journal of cardiology · 2025Review
- Interleukin-10: Genetic and biochemical prediction of sepsis-induced acute kidney injury in critically ill patients in intensive care unit: A cross-sectional study.Journal of the Chinese Medical Association : JCMA · 2024Article
- Major Adverse Cardiovascular Events: The Importance of Serum Levels and Haplotypes of the Anti-Inflammatory Cytokine Interleukin 10.Biomolecules · 2024Observational
- Circulating Regulatory B-Lymphocytes in Patients with Acute Myocardial Infarction: A Pilot Study.Journal of cardiovascular development and disease · 2022Article
- The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches.International journal of molecular sciences · 2022Review
- The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health.Molecular imaging and biology · 2022Review
- A Real Pandora's Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19.Life (Basel, Switzerland) · 2022Review
- Correlation between Serum Lipid Parameters and Interleukin-10 Concentration in Obese Individuals.Journal of obesity & metabolic syndrome · 2021Article
- The Relationship Between Blood Interleukin-10 and Cardiovascular Mortality and All-Cause Mortality After Kidney Transplantation.Risk management and healthcare policy · 2021Article
- Polimorfismo de genes de citocinas: ¿factores de riesgo cardiovascular en la población venezolana?Archivos de cardiologia de Mexico · 2020Article
- Molecular Imaging in Ischemic Heart Disease.Current cardiovascular imaging reports · 2019Review
- The impact of female fetal sex on preeclampsia and the maternal immune milieu.Pregnancy hypertension · 2018Article
- Indoleamine 2,3-Dioxygenase (IDO) Enzyme Links Innate Immunity and Altered T-Cell Differentiation in Non-ST Segment Elevation Acute Coronary Syndrome.International journal of molecular sciences · 2017Article
- Acute coronary syndrome and acute kidney injury: role of inflammation in worsening renal function.BMC cardiovascular disorders · 2017Article
- Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.Oncotarget · 2017Article
- Prognostic performance of interleukin-10 in patients with chest pain and mild to moderate coronary artery lesions-an 8-year follow-up study.Journal of geriatric cardiology : JGC · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo re-evaluate the relation between plasma interleukin-10 (IL-10) concentration at hospital admission and outcome and to investigate the impact of single nucleotide polymorphisms (SNP) in the IL-10 gene in patients with non-ST elevation acute coronary syndrome (ACS).
designDetermination of IL-10 plasma concentrations and genotyping of SNPs in the IL-10 gene in a prospective trial of patients with ACS and in a group of healthy controls. PATIENTS: 3179 patients in the Fragmin and fast revascularisation during InStability in Coronary artery disease II (FRISC II) trial and 393 healthy controls.
main outcome measuresMortality and incidence of myocardial infarction (MI) at 12 months.
resultsThe median and interquartile ranges of IL-10 were 0.8 (0.5-1.0) pg/ml in healthy controls and 1.1 (0.7-1.9) pg/ml in patients (p<0.001). In patients, IL-10 predicted a crude risk increase of death/MI, with the highest risk observed in the fourth quartile (adjusted odds ratio 1.7 (95% confidence interval 1.2 to 2.3)). Adjustment for common risk indicators, including C-reactive protein and interleukin-6, weakened the association to a non-significant level. The 1170 CC genotype weakly predicted increased plasma concentrations of IL-10 in patients (p = 0.04) and in controls (p = 0.03), which was consistent with the modest association of this variant with coronary disease (p = 0.01).
conclusionIn contrast with some previous reports, we conclude that IL-10 reflects a proinflammatory state in patients with ACS and we therefore suggest that IL-10 is as effective a biomarker for the risk prediction of future cardiovascular events as other markers of systemic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.